Drug Profile

Autologous muscle precursor cell therapy - MUVON Therapeutics

Latest Information Update: 25 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Zurich
Developer MUVON Therapeutics
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Urinary-Stress-Incontinence

Most Recent Events

16 Apr 2025 MUVON Therapeutics completes enrolment of patients in phase II clinical trials in Stress incontinence in Switzerland (Transurethral) (NCT05534269)
27 Oct 2022 Phase-II clinical trials in Stress incontinence in Switzerland (Transurethral) (NCT05534269)
08 Sep 2022 Efficacy and adverse events data from a phase I trial in Stress incontinence released by MUVON Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com